Patents by Inventor Takahisa Maruyama

Takahisa Maruyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10301343
    Abstract: According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4?-epi-feudomycin, which are typical impurities possibly contained in 4?-epi-daunorubicin as a starting material, by using an organic acid salt of 4?-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 28, 2019
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Kenichiro Mori, Takuto Umezu, Takahisa Maruyama, Sojiro Shiokawa
  • Publication number: 20180094014
    Abstract: According to the present invention, it is possible to efficiently remove 13-dihydroepi-daunorubicin and 4?-epi-feudomycin, which are typical impurities possibly contained in 4?-epi-daunorubicin as a starting material, by using an organic acid salt of 4?-epi-daunorubicin or a hydrate or solvate thereof as a novel production intermediate, thus making it possible to produce high-purity epirubicin.
    Type: Application
    Filed: March 30, 2016
    Publication date: April 5, 2018
    Applicant: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Kenichiro MORI, Takuto UMEZU, Takahisa MARUYAMA, Sojiro SHIOKAWA
  • Patent number: 8344154
    Abstract: 2-Ethenylthio-type carbapenem derivatives of formula (I) or pharmaceutically acceptable salts thereof are provided. The compounds according to the present invention have potent antimicrobial activity and a wide antimicrobial spectrum against pneumococci including penicillin resistant Streptococcus pneumoniae (PRSP), Haemophilus influenzae including ?-lactamase-negative, ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: January 1, 2013
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Takahisa Maruyama, Yuko Kano, Takashi Ando, Toshiro Sasaki, Kazuhiro Aihara, Toshiki Fujita
  • Publication number: 20100145063
    Abstract: 2-Ethenylthio-type carbapenem derivatives of formula (I) or pharmaceutically acceptable salts thereof are provided. The compounds according to the present invention have potent antimicrobial activity and a wide antimicrobial spectrum against pneumococci including penicillin resistant Streptococcus pneumoniae (PRSP), Haemophilus influenzae including ?-lactamase-negative, ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis.
    Type: Application
    Filed: February 4, 2010
    Publication date: June 10, 2010
    Inventors: Takahisa Maruyama, Yuko Kano, Takashi Ando, Toshiro Sasaki, Kazuhiro Aihara, Toshiki Fujita
  • Patent number: 7687490
    Abstract: An objective of the present invention is to provide compounds that are effective against various resistant bacteria which cause current clinical problems, for example, pneumococci including penicillin resistant Streptococcus pneumoneae (PRSP), Haemophilus influenzae including bata-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: March 30, 2010
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Takahisa Maruyama, Yuko Kano, Takashi Ando, Takehiko Sawabe, Nobuyoshi Baba, Hiromi Takata, Hisashi Suzuki, Kazuhiro Aihara, Toshiki Fujita
  • Publication number: 20070004700
    Abstract: [Objective] An objective of the present invention is to provide compounds that are effective against various resistant bacteria which cause current clinical problems, for example, pneumococci including penicillin resistant Streptococcus pneumoneae (PRSP), Haemophilus influenzae including bata-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis.
    Type: Application
    Filed: April 12, 2006
    Publication date: January 4, 2007
    Applicant: Meiji Seika Kaisha, Ltd.
    Inventors: Takahisa Maruyama, Yuko Kano, Takashi Ando, Toshiro Sasaki, Takehiko Sawabe, Nobuyoshi Baba, Hiromi Takata, Hisashi Suzuki, Kazuhiro Aihara, Toshiki Fujita
  • Patent number: 6908913
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have strong antibiotic activity also against MRSA, PRSP, Influenzavirus, and ?-lactamase producing bacteria and are stable to DHP-1. The carbapenem derivatives according to the present invention are compounds represented by formulae (I) and (II) or pharmaceutically acceptable salts thereof: wherein R1 represents H or methyl, R2 and R3 each independently represent H; halogen; substituted or unsubstituted alkyl; cycloalkyl; substituted or unsubstituted alkylcarbonyl; carbamoyl; substituted or unsubstituted aryl; substituted or unsubstituted alkylthio; morpholinyl; alkylsulfonyl; or formyl, n is 0 (zero) to 4, and Hy represents a substituted or unsubstituted monocyclic or bicyclic heterocyclic group.
    Type: Grant
    Filed: November 22, 2001
    Date of Patent: June 21, 2005
    Assignee: Meiji Seiki Kaisha, Ltd.
    Inventors: Yuko Kano, Yasuo Yamamoto, Takahisa Maruyama, Takehiko Sawabe, Eiki Shitara, Kazuhiro Aihara, Kunio Atsumi, Takashi Ida
  • Patent number: 6825187
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts thereof: wherein R1 represents H or methyl; R2 and R3 each independently represent H, halogen, lower alkyl or the like; R4 represents optionally substituted lower alkylthio or the like; and R5 represents optionally substituted lower alkyl or the like.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: November 30, 2004
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Yuko Kano, Takahisa Maruyama, Yasuo Yamamoto, Eiki Shitara, Toshiro Sasaki, Kazuhiro Aihara, Kunio Atsumi, Katsuyoshi Iwamatsu, Takashi Ida
  • Publication number: 20040038967
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have strong antibiotic activity also against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase producing bacteria and are stable to DHP-1.
    Type: Application
    Filed: February 14, 2003
    Publication date: February 26, 2004
    Inventors: Yuko Kano, Yasuo Yamamoto, Takahisa Maruyama, Takehiko Sawabe, Eiki Shitara, Kazuhiro Aihara, Kunio Atsumi, Takashi Ida
  • Patent number: 6680313
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts thereof: wherein R1 represents H or methyl; R2 and R3 represent H, a halogen atom, alkyl or the like; and R4 represents substituted lower alkylthio or the like.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: January 20, 2004
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Yuko Kano, Takahisa Maruyama, Yumiko Sambongi, Kazuhiro Aihara, Kunio Atsumi, Kastuyoshi Iwamatsu, Takashi Ida
  • Patent number: 6677331
    Abstract: Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the carbapenem ring have high anti microbial activities against &bgr;-lactamase producing bacteria, MRSA, resistant-Pseudomonas aeruginosa, PRSP, enterococci, and influenza, and high stabilities to DHP-1.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: January 13, 2004
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Yuko Kano, Toshiro Sasaki, Yumiko Sambongi, Kiyoshi Tanabe, Yoshihisa Akiyama, Hideo Kitagawa, Takahisa Maruyama, Hiromasa Takizawa, Takashi Ando, Kazuhiro Aihara, Kunio Atsumi, Katsuyoshi Iwamatsu, Takashi Ida
  • Publication number: 20030149016
    Abstract: Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the, carbapenem ring have high anti-microbial activities against &bgr;-lactamase producing bacteria, MRSA, resistant-Pseudomonas aeruginosa, PRSP, enterococci, and influenza, and high stabilities to DHP-1.
    Type: Application
    Filed: August 14, 2002
    Publication date: August 7, 2003
    Inventors: Yuko Kano, Toshiro Sasaki, Yumiko Sambongi, Kiyoshi Tanabe, Yoshihisa Akiyama, Hideo Kitagawa, Takahisa Maruyama, Hiromasa Takizawa, Takashi Ando, Kazuhiro Aihara, Kunio Atsumi, Katsuyoshi Iwamatsu, Takashi Ida
  • Publication number: 20030027809
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1.
    Type: Application
    Filed: July 25, 2002
    Publication date: February 6, 2003
    Inventors: Yuko Kano, Takahisa Maruyama, Yumiko Sambongi, Kazuhiro Aihara, Kunio Atsumi, Kastuyoshi Iwamatsu, Takashi Ida
  • Publication number: 20030022881
    Abstract: An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1.
    Type: Application
    Filed: July 25, 2002
    Publication date: January 30, 2003
    Inventors: Yuko Kano, Takahisa Maruyama, Yasuo Yamamoto, Eiki Shitara, Toshiro Sasaki, Kazuhiro Aihara, Kunio Atsumi, Katsuyoshi Iwamatsu, Takashi Ida
  • Patent number: 6458780
    Abstract: Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the carbapenem ring have high anti-microbial activities against &bgr;-lactamase producing bacteria, MRSA, resistant-Pseudomonas aeruginosa, PRSP, enterococci, and influenza, and high stabilities to DHP-1.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: October 1, 2002
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Yuko Kano, Toshiro Sasaki, Yumiko Sambongi, Kiyoshi Tanabe, Yoshihisa Akiyama, Hideo Kitagawa, Takahisa Maruyama, Hiromasa Takizawa, Takashi Ando, Kazuhiro Aihara, Kunio Atsumi, Katsuyoshi Iwamatsu, Takashi Ida